These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 35373329)

  • 1. Cardiac allograft vasculopathy in a long-term follow-up after heart transplantation: Role of remnant cholesterol in residual inflammation.
    Alyaydin E; Pogoda C; Dell Aquila A; Martens S; Tuleta I; Reinecke H; Sindermann JR
    Cardiol J; 2022; 29(5):782-790. PubMed ID: 35373329
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in Outcomes of Cardiac Allograft Vasculopathy Over 30 Years Following Heart Transplantation.
    Tremblay-Gravel M; Racine N; de Denus S; Ducharme A; Pelletier GB; Giraldeau G; Liszkowski M; Parent MC; Carrier M; Fortier A; White M
    JACC Heart Fail; 2017 Dec; 5(12):891-901. PubMed ID: 29191295
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Suppressive effects of conversion from mycophenolate mofetil to everolimus for the development of cardiac allograft vasculopathy in maintenance of heart transplant recipients.
    Watanabe T; Seguchi O; Nishimura K; Fujita T; Murata Y; Yanase M; Sato T; Sunami H; Nakajima S; Hisamatsu E; Sato T; Kuroda K; Hieda M; Wada K; Hata H; Ishibashi-Ueda H; Miyamoto Y; Fukushima N; Kobayashi J; Nakatani T
    Int J Cardiol; 2016 Jan; 203():307-14. PubMed ID: 26523360
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Timing of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor initiation and allograft vasculopathy progression and outcomes in heart transplant recipients.
    Asleh R; Briasoulis A; Pereira NL; Boilson BA; Edwards BS; Adigun R; Maltais S; Daly RC; Lerman A; Kushwaha SS
    ESC Heart Fail; 2018 Dec; 5(6):1118-1129. PubMed ID: 30019530
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Statin therapy in cardiac allograft vasculopathy progression in heart transplant patients: Does potency matter?
    Sieg A; Weeks P; Krustchinsky L; Rajapreyar I
    Transplant Rev (Orlando); 2016 Jul; 30(3):178-86. PubMed ID: 27079752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evidence-based pharmacotherapy for prevention and management of cardiac allograft vasculopathy.
    Mallah SI; Atallah B; Moustafa F; Naguib M; El Hajj S; Bader F; Mehra MR
    Prog Cardiovasc Dis; 2020; 63(3):194-209. PubMed ID: 32205133
    [TBL] [Abstract][Full Text] [Related]  

  • 7. De novo sirolimus with low-dose tacrolimus versus full-dose tacrolimus with mycophenolate mofetil after heart transplantation--8-year results.
    Guethoff S; Stroeh K; Grinninger C; Koenig MA; Kleinert EC; Rieger A; Mayr T; von Ziegler F; Reichart B; Hagl C; Schramm R; Kaczmarek I; Meiser BM
    J Heart Lung Transplant; 2015 May; 34(5):634-42. PubMed ID: 25701373
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Platelet aggregation and response to aspirin therapy in cardiac allograft vasculopathy.
    Bjerre KP; Clemmensen TS; Berg K; Poulsen SH; Hvas AM; Grove EL; Løgstrup BB; Jakobsen L; Thim T; Kristensen SD; Eiskjær H
    J Heart Lung Transplant; 2020 Apr; 39(4):371-378. PubMed ID: 32067865
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of cytomegalovirus infection in the development of cardiac allograft vasculopathy after heart transplantation.
    Delgado JF; Reyne AG; de Dios S; López-Medrano F; Jurado A; Juan RS; Ruiz-Cano MJ; Dolores Folgueira M; Gómez-Sánchez MÁ; Aguado JM; Lumbreras C
    J Heart Lung Transplant; 2015 Aug; 34(8):1112-9. PubMed ID: 25940077
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of metabolic syndrome on development of cardiac allograft vasculopathy in the transplanted heart.
    Sánchez-Gómez JM; Martínez-Dolz L; Sánchez-Lázaro I; Almenar L; Sánchez-Lacuesta E; Muñoz-Giner B; Portolés M; Rivera M; Valera-Román A; González-Juanatey JR; Tejada-Ponce D; Agüero J; Buendía F; Salvador A
    Transplantation; 2012 Jan; 93(1):106-11. PubMed ID: 22134367
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Carbohydrate Metabolism Disorders in Relation to Cardiac Allograft Vasculopathy (CAV) Intensification in Heart Transplant Patients According to the Grading Scheme Developed by the International Society for Heart and Lung Transplantation (ISHLT).
    Zielińska K; Kukulski L; Wróbel M; Przybyłowski P; Rokicka D; Strojek K
    Ann Transplant; 2022 Feb; 27():e933420. PubMed ID: 35165250
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preventing cardiac allograft vasculopathy: long-term beneficial effects of mycophenolate mofetil.
    Kaczmarek I; Ertl B; Schmauss D; Sadoni S; Knez A; Daebritz S; Meiser B; Reichart B
    J Heart Lung Transplant; 2006 May; 25(5):550-6. PubMed ID: 16678034
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of cardiac allograft vasculopathy in heart and heart-lung transplantations: a 15-year retrospective study.
    Guihaire J; Mercier O; Flécher E; Aymami M; Fattal S; Chabanne C; Leroy Ladurie F; Lelong B; Cerrina J; Langanay T; Mussot S; Fabre D; De Latour B; Corbineau H; Verhoye JP; Dartevelle P; Leguerrier A; Fadel E
    J Heart Lung Transplant; 2014 Jun; 33(6):636-43. PubMed ID: 24630860
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term outcome of cardiac allograft vasculopathy: Importance of the International Society for Heart and Lung Transplantation angiographic grading scale.
    Van Keer JM; Van Aelst LNL; Rega F; Droogne W; Voros G; Meyns B; Vanhaecke J; Emonds MP; Janssens S; Naesens M; Van Cleemput J
    J Heart Lung Transplant; 2019 Nov; 38(11):1189-1196. PubMed ID: 31543298
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pravastatin therapy is associated with reduction in coronary allograft vasculopathy in pediatric heart transplantation.
    Mahle WT; Vincent RN; Berg AM; Kanter KR
    J Heart Lung Transplant; 2005 Jan; 24(1):63-6. PubMed ID: 15653381
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimal low-density lipoprotein concentration for cardiac allograft vasculopathy prevention.
    Harris J; Teuteberg J; Shullo M
    Clin Transplant; 2018 May; 32(5):e13248. PubMed ID: 29603413
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predicting the development of cardiac allograft vasculopathy.
    Seki A; Fishbein MC
    Cardiovasc Pathol; 2014; 23(5):253-60. PubMed ID: 24972526
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blood glutathione as a marker of cardiac allograft vasculopathy in heart transplant recipients.
    De Chiara B; Bigi R; Campolo J; Parolini M; Turazza F; Masciocco G; Frigerio M; Fiorentini C; Parodi O
    Clin Transplant; 2005 Jun; 19(3):367-71. PubMed ID: 15877800
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of everolimus introduction on cardiac allograft vasculopathy--results of a randomized, multicenter trial.
    Arora S; Ueland T; Wennerblom B; Sigurdadottir V; Eiskjær H; Bøtker HE; Ekmehag B; Jansson K; Mortensen SA; Saunamaki K; Simonsen S; Gude E; Bendz B; Solbu D; Aukrust P; Gullestad L
    Transplantation; 2011 Jul; 92(2):235-43. PubMed ID: 21677600
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progression of cardiac allograft vasculopathy assessed by serial three-vessel quantitative coronary angiography.
    Zanchin C; Yamaji K; Rogge C; Lesche D; Zanchin T; Ueki Y; Windecker S; Mohacsi P; Räber L; Sigurdardottir V
    PLoS One; 2018; 13(8):e0202950. PubMed ID: 30148864
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.